



JE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/571,991		
		Filing Date	March 15, 2006		
		First Named Inventor	Hennequin		
		Art Unit	4161		
		Examiner Name	Douglas M. WILLIS		
Sheet	1	of	10	Attorney Docket Number	09963.0008-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
		7,294,629	11-13-2007	Kitano et al.	
		7,148,230	12-12-2006	Bradbury et al.	
		7,119,084	10-10-2006	Himmelsbach et al.	
		6,972,288	12-06-2005	Himmelsbach et al.	
		6,924,285	08-02-2005	Himmelsbach et al.	
		6,740,651	05-25-2004	Himmelsbach et al.	
		6,653,305	11-25-2003	Himmelsbach et al.	
		6,627,651	09-30-2003	Shirishi et al.	
		6,562,319	05-13-2003	Mishani et al.	
		6,384,223	05-07-2002	Gletsos	
		6,326,373	12-04-2001	Uckun et al.	
		6,313,130	11-06-2001	Uckun et al.	
		6,297,258	10-02-2001	Wissner et al.	
		6,225,318	05-01-2001	Sobolov-Jaynes et al.	
		6,177,433	01-23-2001	Uckun et al.	
		6,126,917	10-03-2000	Mishani et al.	
		6,117,433	09-12-2000	Edens et al.	
		6,046,206	04-04-2000	Pamukcu et al.	
		6,004,967	12-21-1999	McMahon et al.	
		5,962,458	10-05-1999	Lohmann et al.	
		5,929,080	07-27-1999	Frost et al.	
		5,866,572	02-02-1999	Barker et al.	
		5,821,246	10-13-1998	Brown et al.	
		5,770,603	06-23-1998	Gibson	
		5,770,599	06-23-1998	Gibson	
		5,747,498	05-05-1999	Schnur et al.	
		5,721,237	02-24-1998	Myers et al.	
		5,616,582	04-01-1997	Barker	
		5,457,105	10-10-1995	Barker	
		5,405,843	04-11-1995	Fukazawa et al.	
		5,252,586	10-12-1993	Cain et al.	

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	4161
				Examiner Name	Douglas M. WILLIS
Sheet	2	of	10	Attorney Docket Number	09963.0008-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No.	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code (if known)			
		4,921,863	05-01-1990	Sugimoto et al.	
		4,640,920	02-03-1987	Boyle et al.	
		4,335,127	06-12-1982	Vanderberk et al.	
		4,322,420	06-01-1982	Coski	
		3,985,749	10-12-1976	Foster	
		2008/0096881	04-24-2008	Hennequin et al.	
		2007/0099943	05-03-2007	Bradbury et al.	
		2007/0043010	02-22-2007	Bradbury et al.	
		2007/0037837	02-15-2007	Hennequin et al.	
		2006/0270672	11-30-2006	Himmelsbach et al.	
		2005/0215574	09-29-2005	Bradbury et al.	
		2005/0165035	07-28-2005	Bradbury	
		2005/0182043	08-18-2005	Himmelsbach et al.	
		2004/0176361	09-09-2004	Fujio et al.	
		2004/0048880	03-11-2004	Himmelsbach et al.	
		2004/0044014	03-04-2004	Himmelsbach et al.	
		2003/0158196	08-21-2003	Jung et al.	
		2003/0149062	08-07-2003	Jung et al.	
		2002/0177601	11-28-2002	Himmelsbach et al.	
		2002/0173509	11-21-2002	Himmelsbach et al.	
		2002/0173646	11-21-2002	Thomas et al.	
		2002/0169180	11-14-2002	Himmelsbach et al.	
		2002/0128553	09-12-2002	Mishani et al.	
		2002/0082271	06-27-2002	Himmelsbach et al.	
		2002/0082270	06-27-2002	Himmelsbach et al.	
		2002/0049197	04-25-2002	Himmelsbach et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		WO 2007/063293	06-07-2007	Astrazeneca UK Ltd		

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	4161
				Examiner Name	Douglas M. WILLIS
Sheet	3	of	10	Attorney Docket Number	09963.0008-00000

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code	Number Kind Code (if known)			
		WO	2007/063291	06-07-2007	Astrazeneca UK Ltd	
		WO	2007/034144	03-29-2007	Astrazeneca UK Ltd	
		WO	2007/034143	03-29-2007	Astrazeneca UK Ltd	
		WO	2006/117523	11-09-2006	Astrazeneca UK Ltd	
		WO	2006/117521	11-09-2006	Astrazeneca UK Ltd	
		WO	2006/092574	09-08-2006	Astrazeneca UK Ltd	
		WO	2006/092573	09-08-2006	Astrazeneca UK Ltd	
		WO	2006/090163	08-31-2006	Astrazeneca UK Ltd	
		WO	2006/064196	06-22-2006	Astrazeneca UK Ltd	
		WO	2005/118572	12-15-2005	Astrazeneca UK Ltd	
		WO	2005/075439	08-15-2005	Astrazeneca UK Ltd	
		WO	2005/051923	06-09-2005	Astrazeneca UK Ltd	
		WO	2005/041973	05-12-2005	Jung et al.	
		WO	2005/030765	04-07-2005	Barlaam et al.	
		WO	2005/030757	04-07-2005	Bradbury et al.	
		WO	2005/028470	03-31-2005	Bradbury et al.	
		WO	2005/028469	03-31-2005	Bradbury et al.	
		WO	2005/026157	03-24-2005	Astrazeneca AB	
		WO	2005/026156	03-24-2005	Astrazeneca AB	
		WO	2005/026152	03-24-2005	Astrazeneca AB	
		WO	2005/026151	03-24-2005	Bradbury et al.	
		WO	2005/026150	03-24-2005	Astrazeneca AB	
		WO	2005/012290	02-10-2005	Bradbury et al.	
		WO	2004/096226	11-11-2004	Astrazeneca UK Ltd	
		WO	2004/093880	11-04-2004	Bradbury et al.	
		WO	2004/064718	08-05-2004	Mishani et al.	
		WO	2003/064413	08-07-2003	Astrazeneca UK Ltd	
		WO	2003/049740	06-19-2003	Kath et al.	
		WO	2003/045395	06-05-2003	Moore et al.	
		WO	2003/045364	06-05-2003	Moore et al.	
		WO	2003/040109	05-15-2003	Hennequin et al.	

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	4161
				Examiner Name	Douglas M. WILLIS
Sheet	4	of	10	Attorney Docket Number	09963.0008-00000

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		WO 2003/040108	05-15-2003	Hennequin et al.		
		WO 2003/000188	01-03-2003	Wang et al.		
		WO 02/094760	11-28-2002	Schnyder et al.		
		WO 02/092579	11-21-2002	Hennequin et al.		
		WO 02/092578	11-21-2002	Hennequin et al.		
		WO 02/092577	11-21-2002	Hennequin et al.		
		WO 02/076976	10-03-2002	Nagarathnam et al.		
		WO 02/073235	09-19-2002	Levitzki et al.		
		WO 02/068409	09-06-2002	Claiborne et al..		
		WO 02/066445	08-29-2002	Mitsubishi Pharma.		Abstract & US 7,294,629
		WO 02/062767	08-15-2002	Japan Energy Corp.		Abstract
		WO 02/056882	07-25-2002	Davies		
		WO 02/50043	06-27-2002	Himmelsbach et al.		
		WO 02/48117	06-20-2002	Matsuoka et al.		
		WO 02/44166	06-06-2002	Boyle et al.		
		WO 02/34744	05-02-2002	Lambert et al.		
		WO 02/34711	05-02-2002	Babu et al.		
		WO 02/30924	04-18-2002	Lambert et al.		
		WO 02/24684	03-28-2002	Davies et al.		
		WO 02/18376	03-07-2002	Himmelsbach et al.		Abstract & CA2417097
		WO 02/18373	03-07-2002	Himmelsbach et al.		Abstract & CA2417050
		WO 02/18372	03-07-2002	Himmelsbach et al.		Abstract & CA2417652
		WO 02/18370	03-07-2002	Himmelsbach et al.		Abstract & CA2417042
		WO 02/18351	03-07-2002	Himmelsbach et al.		Abstract & CA2417897
		WO 02/16352	02-28-2002	Hennequin et al.		
		WO 01/98277	12-27-2001	Kath		
		WO 01/94341	12-13-2001	Hennequin et al.		
		WO 01/77085	10-18-2001	Hennequin et al.		
		WO 01/76586	10-18-2001	Furr		

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	4161
				Examiner Name	Douglas M. WILLIS
Sheet	5	of	10	Attorney Docket Number	09963.0008-00000

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		WO 01/32651	05-10-2001	Hennequin et al.		
		WO 01/66099	09-13-2001	Hennequin et al.		
		WO 01/045641	06-28-2001	Uckun		
		WO 01/032632	05-10-2001	Ambler et al.		
		WO 01/21597	03-29-2001	Mortlock et al.		
		WO 01/21596	03-29-2001	Mortlock et al.		
		WO 01/21595	03-29-2001	Mortlock et al.		
		WO 01/21594	03-29-2001	Mortlock et al.		
		WO 01/012227	02-22-2001	Amer. Cyanamid Co.		
		WO 01/007432	02-01-2001	Davies		
		WO 01/04102	01-18-2001	Crawley et al.		
		WO 00/78735	12-28-2000	Himmelsbach et al.		Abstract & CA2375259
		WO 00/073260	12-07-2000	Langham et al.		
		WO 00/68203	11-16-2000	Shiraishi et al.		Abstract & US 6,627,651
		WO 00/56720	09-28-2000	Uckun et al.		
		WO 00/56338	09-28-2000	Yiv et al.		
		WO 00/55162	09-21-2000	Himmelsbach et al.		
		WO 00/55141	09-21-2000	Himmelsbach et al.		
		WO 00/51991	09-08-2000	Himmelsbach et al.		
		WO 00/51587	09-08-2000	Uckun et al.		
		WO 00/20402	04-13-2000	Cumming		
		WO 00/12497	03-09-2000	Chakravarty et al.		
		WO 00/10981	03-02-2000	Navara et al.		
		WO 00/06555	02-10-2000	Amer. Home Prods.		
		WO 00/47212	08-17-2000	Hennequin et al.		
		WO 00/44728	08-03-2000	Kath et al.		
		WO 00/24718	05-04-2000	Timmers et al.		
		WO 00/18740	04-06-2000	American Cyanamid Co.		
		WO 00/09481	02-24-2000	Takeda Chemical Indus. Ltd.		Of claims

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	4161
				Examiner Name	Douglas M. WILLIS
Sheet	6	of	10	Attorney Docket Number	09963.0008-00000

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		WO 00/00202	01-06-2000	Uckun		
		WO 99/61428	12-02-1999	Wayne Hughes Inst.		
		WO 99/35132	07-15-1999	Cockerill et al.		
		WO 99/24037	05-20-1999	American Cyanamid		
		WO 99/10349	03-04-1999	Hennequin et al.		
		WO 99/09016	02-25-1999	Wissner et al.		
		WO 99/06378	02-11-1999	Bridges		
		WO 98/50370	11-12-1998	Tang et al.		
		WO 98/50038	11-12-1998	Amer. Cyanamid Co.		
		WO 98/38984	09-11-1998	Shenoy et al.		
		WO 98/13354	04-02-1998	Thomas et al.		
		WO 98/02434	01-22-1998	Cockerill et al.		
		WO 97/42187	11-13-1997	Thomas et al.		
		WO 97/38994	10-23-1997	Zeneca Limited		
		WO 97/38983	10-23-1997	Bridges et al.		
		WO 97/32856	09-12-1997	Thomas et al.		
		WO 97/30035	08-21-1997	Thomas et al.		
		WO 97/30034	08-21-1997	Barker et al.		
		WO 97/30044	08-21-1997	Zeneca Ltd.		
		WO 97/22596	06-26-1997	Lohmann et al.		
		WO 97/18813	05-29-1997	Kim et al.		
		WO 97/11692	04-03-1997	Sharpe et al.		
		WO 97/03069	01-30-1997	Cockerill et al.		
		WO 96/39145	12-12-1996	Myers et al.		
		WO 96/33981	10-31-1996	Barker		
		WO 96/33980	10-31-1996	Gibson		
		WO 96/33979	10-31-1996	Barker		
		WO 96/33978	10-31-1996	Barker		
		WO 96/33977	10-31-1996	Barker		
		WO 96/30347	10-03-1996	Schnur et al.		

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	4161
				Examiner Name	Douglas M. WILLIS
Sheet	7	of	10	Attorney Docket Number	09963.0008-00000

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		WO 96/016960	06-06-1996	Barker		
		WO 96/15118	05-23-1996	Brown et al.		
		WO 96/09294	03-28-1996	Hudson et al.		
		WO 95/24190	09-14-1995	Chen et al.		
		WO 95/15758	06-15-1995	Myers et al.		
		WO 95/03283	02-02-1995	Zeneca Limited		
		WO 95/00146	01-05-1995	Morris et al.		
		WO 94/27965	12-08-1994	Clark et al.		
		WO 93/017682	09-16-1993	Abbott Labs.		
		WO 93/08170	04-29-1993	American Home Prods		
		WO 92/20642	11-26-1992	Spada et al.		
		WO 92/14746	09-03-1992	Schonecker et al.		
		WO 88/02365	04-07-1988	Eisai Co.Ltd.		Abstract & EP0288563
		CA 2 417 907 A1	01-30-2003	Himmelsbach et al.		
		CA 2 417 050 A1	03-07-2002	Himmelsbach et al.		
		CA 2 417 652 A1	01-28-2003	Himmelsbach et al.		
		CA 2 417 042 A1	03-07-2002	Himmelsbach et al.		
		CA 2 417 897 A1	01-30-2003	Himmelsbach et al.		
		CA 2 375 259 A1	12-28-2000	Himmelsbach et al.		
		EP 1 369 418	12-10-2003	Mitsubishi Corp.		
		EP 1 283 039	02-12-2003	Takeda Chem. Indus.		
		EP 1 230 919	08-14-2002	Warner Lambert Co.		
		EP 0 635 507	09-15-1999	Barker et al.		
		EP 0 837 063	04-22-1998	Pfizer Inc.		
		EP 0 787 722	08-06-1997	Amer. Cyanamid Co.		
		EP 0 602 851	10-09-1996	Barker et al.		
		EP 0 520 722	12-27-1996	Barker et al.		
		EP 0 607 439	07-27-1994	Takase et al.		
		EP 0 326 330	08-02-1989	Arnold et al.		

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
-----------------------	------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	4161
				Examiner Name	Douglas M. WILLIS
Sheet	8	of	10	Attorney Docket Number	09963.0008-00000

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code Number Kind Code (if known)				
		EP 0 288 563	11-02-1988	Eisai Co.		
		GB 2,295,387	05-29-1996	Glaxo Inc.		
		GB 2,160,201	12-18-1985	Boyle et al.		
		GB 2,033,894	05-29-1980	Kobayashe et al.		
		JP 11-189586	07-13-1999	Kirin Brewery		Yes

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Ballard, P. et al., "Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics," Bioorg. Med. Chem. lett. 16:4908-4912 (2006).	
		Barker et al., Studies Leading to the Identification of ZD1839 (Iressa™): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer," Bioorg. Med. Chem. Lett. 11(14): 1911-1914 (2001).	
		Bridges et al., "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor," J. Med. Chem. 39: 267-276 (1996).	
		Chevalier et al., "Induction of DNA replication by peroxisome proliferators is independent of both tumour necrosis factor (alpha) priming and EGF-receptor tyrosine kinase activity," J. Cell Sci. 112(24): 4785-4791 (1999)	
		Denny et al., "Structure-Activity Relationships for 4-Anilinoquinazolines as Potent Inhibitors at the ATP Binding Site for the Epidermal Growth Factor Receptor <i>in vitro</i> ," Clinical and Experimental Pharmacology and Physiology 23:424-427 (1996).	
		Gazit et al., "Tyrophostins IV-Highly Potent Inhibitors . . . Relationship Study of 4-Anilidoquinazolines," Bioorganic & Medicinal Chemistry 48(8): 1203-1207 (1996)	
		Ghosh et al., "Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents," Anti-Cancer Drug Design 14, 403-410 (1999)	
		Hennequin et al., "Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors," J. Med. Chem. 42: 5369-5389 (1999)	
		March, J., Advanced Organic Chemistry -- Reactions, Mechanisms, and Structure, 4 th Ed., © 1992, John Wiley & Sons, New York, NY, page 357.	
		Mendelsohn et al., "Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer," J. Clinical Oncology 21(14): 2787-2799 (2003).	

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/571,991
				Filing Date	March 15, 2006
				First Named Inventor	Hennequin
				Art Unit	4161
				Examiner Name	Douglas M. WILLIS
Sheet	9	of	10	Attorney Docket Number	09963.0008-00000

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Mendelsohn, "Targeting the Epidermal Growth Factor Receptor for Cancer Therapy," Journal of Clinical Oncology 20(18s):2s-13s (2002)	
		Myers et al., "The preparation and SAR of 4-(anilion), 4-(phenoxy), and 4-(thiophenoxy)-quinzolines: inhibitors of p56lck and EGF-R tyrosine kinase activity," Biorg. Med. Chem. Lett. 7(4): 417-420 (1997)	
		Pao et al., "Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions," Journal of Clinical Oncology 23(11):1-13 (2005)	
		Rewcastle et al., "Tyrosine Kinase Inhibitors. 5 ... 4-(Phenylamino)quinazolines as Potent ... Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor," J. Med. Chem. 38:3482-3487 (1995)	
		Singh et al., "Inhibitors of the epidermal growth factor receptor protein tyrosine kinase: A quantitative structure-activity relationship analysis," J. Enzyme Inhibition 13:125-134 (1998)	
		Smaill et al., "Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phe-nylamino)pyrido," J. Med. Chem. 43(16):3199 (2000)	
		Stamos et al., "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor," J. Bio. Chem. 277(48):46265-46272 (2002).	
		Traxler, "Oncologic, Endocrine & Metabolic: Protein tyrosine kinase inhibitors in cancer treatment," Expert Opinion on Therapeutic Patents 7:571-588 (1997).	
		Traxler, "Monthly Focus: Oncologic, Endocrine & Metabolic: Tyrosine kinase inhibitors in cancer treatment (Part II)," Expert Opinion on Therapeutic Patents 8:1599-1625 (1998).	
		Tsou et al., "6- Substituted-4-(3-bromophenylamino)quinazolines As Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (Egfr) and Human Epidermal Growth Factor Receptor (Her-2) Tyrosine Kinases with Enhanced Antitumor Activity," J. Med. Chem. 44:2719-2734 (2001).	
		Vema et al., "Design of EGFR Kinase Inhibitors: A Ligand-Based Approach and Its Confirmation with Structure-Based Studies," Bioorg. Med. Chem. 11:4643-4653 (2003).	
		Wright et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines," Bioorg. Med. Chem. Lett. 11(1):17-21 (2001)	
		Decision in Patent Interferences 105,595 McK and 105,596 McK dated June 17, 2008.	
		English Translation of Office Action in Japanese Patent Appln. No. 2003-580299, the Japanese counterpart of the present application, dated May 11, 2006.	

Examiner Signature	/Douglas Willis/	Date Considered	05/18/2009
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.W./

